Journal article · 2021 · Open access

Wnt/β-Catenin Inhibition Disrupts Carboplatin Resistance in Isogenic Models of Triple-Negative Breast Cancer

Willy Antoni Abreu de Oliveira, Stijn Moens, Youssef El Laithy, Bernard K. van der Veer, Paraskevi Athanasouli, Emanuela Elsa Cortesi, Maria Francesca Baietti, Kian Peng Koh, Juan‐José Ventura, Frédéric C. Amant, Daniela Annibali, Frederic Lluís

Frontiers in Oncology, 11, 705384 · Published 22 July 2021 · DOI 10.3389/fonc.2021.705384

Open full textCite this paper

In brief

“Wnt/β-Catenin Inhibition Disrupts Carboplatin Resistance in Isogenic Models of Triple-Negative Breast Cancer” is a 2021 journal article by Willy Antoni Abreu de Oliveira and 11 co-authors, published in Frontiers in Oncology. OpenAlex counts 45 citations as of 21 November 2026. It is open access under a CC BY licence: the full text is free to read at Frontiers in Oncology.

Citations
45
Most cited in
2025 (11)
Field-weighted impact
1.49
References
99
Authors
12

Abstract

Triple-Negative Breast Cancer (TNBC) is the most aggressive breast cancer subtype, characterized by limited treatment options and higher relapse rates than hormone-receptor-positive breast cancers. Chemotherapy remains the mainstay treatment for TNBC, and platinum salts have been explored as a therapeutic alternative in neo-adjuvant and metastatic settings. However, primary and acquired resistance to chemotherapy in general and platinum-based regimens specifically strongly hampers TNBC management. In this study, we used carboplatin-resistant in vivo patient-derived xenograft and isogenic TNBC cell-line models and detected enhanced Wnt/β-catenin activity correlating with an induced expression of stem cell markers in both resistant models. In accordance, the activation of canonical Wnt signaling in parental TNBC cell lines increases stem cell markers' expression, formation of tumorspheres and promotes carboplatin resistance. Finally, we prove that Wnt signaling inhibition resensitizes resistant models to carboplatin both in vitro and in vivo, suggesting the synergistic use of Wnt inhibitors and carboplatin as a therapeutic option in TNBC. Here we provide evidence for a prominent role of Wnt signaling in mediating resistance to carboplatin, and we establish that combinatorial targeting of Wnt signaling overcomes carboplatin resistance enhancing chemotherapeutic drug efficacy.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

de Oliveira, W. A. A., Moens, S., El Laithy, Y., van der Veer, B. K., Athanasouli, P., Cortesi, E. E., Baietti, M. F., Koh, K. P., Ventura, J., Amant, F. C., Annibali, D., & Lluís, F. (2021). Wnt/β-Catenin Inhibition Disrupts Carboplatin Resistance in Isogenic Models of Triple-Negative Breast Cancer. Frontiers in Oncology, 11, 705384. https://doi.org/10.3389/fonc.2021.705384

MLA 9

de Oliveira, Willy Antoni Abreu, et al. “Wnt/β-Catenin Inhibition Disrupts Carboplatin Resistance in Isogenic Models of Triple-Negative Breast Cancer.” Frontiers in Oncology, vol. 11, 2021, p. 705384. https://doi.org/10.3389/fonc.2021.705384.

Chicago

de Oliveira, Willy Antoni Abreu, Stijn Moens, Youssef El Laithy, Bernard K. van der Veer, Paraskevi Athanasouli, Emanuela Elsa Cortesi, Maria Francesca Baietti, et al. 2021. “Wnt/β-Catenin Inhibition Disrupts Carboplatin Resistance in Isogenic Models of Triple-Negative Breast Cancer.” Frontiers in Oncology 11: 705384. https://doi.org/10.3389/fonc.2021.705384.

Harvard

de Oliveira, W. A. A. et al. (2021) ‘Wnt/β-Catenin Inhibition Disrupts Carboplatin Resistance in Isogenic Models of Triple-Negative Breast Cancer’, Frontiers in Oncology, 11, p. 705384. doi:10.3389/fonc.2021.705384.

IEEE

W. A. A. de Oliveira et al., “Wnt/β-Catenin Inhibition Disrupts Carboplatin Resistance in Isogenic Models of Triple-Negative Breast Cancer,” Frontiers in Oncology, vol. 11, p. 705384, 2021, doi: 10.3389/fonc.2021.705384.

BibTeX

@article{deoliveira2021catenin,
  title     = {{Wnt/β-Catenin Inhibition Disrupts Carboplatin Resistance in Isogenic Models of Triple-Negative Breast Cancer}},
  author    = {de Oliveira, Willy Antoni Abreu and Moens, Stijn and El Laithy, Youssef and van der Veer, Bernard K. and Athanasouli, Paraskevi and Cortesi, Emanuela Elsa and Baietti, Maria Francesca and Koh, Kian Peng and Ventura, Juan‐José and Amant, Frédéric C. and Annibali, Daniela and Lluís, Frederic},
  journal   = {Frontiers in Oncology},
  year      = {2021},
  volume    = {11},
  pages     = {705384},
  doi       = {10.3389/fonc.2021.705384},
  url       = {https://doi.org/10.3389/fonc.2021.705384}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202111
202277
20231010
202466
20251111
202699

Its field-weighted citation impact is 1.49: it has been cited 1.49 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer

  • triple-negative breast cancer
  • carboplatin resistance
  • Wnt/β-catenin signaling
  • Wnt inhibitors
  • chemoresistance
  • cancer stemness
  • stem cell markers
  • tumor spheres

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

de Oliveira, W. A. A., Moens, S., El Laithy, Y., van der Veer, B. K., Athanasouli, P., Cortesi, E. E., Baietti, M. F., Koh, K. P., Ventura, J., Amant, F. C., Annibali, D., & Lluís, F. (2021). Wnt/β-Catenin Inhibition Disrupts Carboplatin Resistance in Isogenic Models of Triple-Negative Breast Cancer. Frontiers in Oncology, 11, 705384. https://doi.org/10.3389/fonc.2021.705384

How many times has this paper been cited?

45 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Frontiers in Oncology: sign in and open the full text from this page.

Who wrote this paper?

Willy Antoni Abreu de Oliveira, Stijn Moens, Youssef El Laithy, Bernard K. van der Veer, Paraskevi Athanasouli, Emanuela Elsa Cortesi, Maria Francesca Baietti, Kian Peng Koh, Juan‐José Ventura, Frédéric C. Amant, Daniela Annibali, Frederic Lluís.

What is the DOI of this paper?

10.3389/fonc.2021.705384, permanently at https://doi.org/10.3389/fonc.2021.705384. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.